Drug intelligence / Profile preview

docetaxel + seribantumab

Development stage: Discontinued
Lead developer: Elevation Oncology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Docetaxel + seribantumab is a combination therapy consisting of docetaxel, a taxane chemotherapy agent, and seribantumab, a fully human IgG2 monoclonal antibody that targets HER3 (ErbB3). Seribantumab works by blocking heregulin (HRG) binding to HER3 and downregulating the receptor, which inhibits downstream signaling pathways involved in tumor growth. This combination was investigated for the treatment of heregulin-positive non-small cell lung cancer (NSCLC).

Targets

TUBB (Tubulin (alpha and beta subunits))ERBB3 (Erb-b2 receptor tyrosine kinase 3)

Beyond the preview

Go deeper on docetaxel + seribantumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + seribantumab.

Explore the full profile